This content is machine translated Non-small cell lung cancer Management of locally advanced NSCLC – where are we heading? Lung cancer is the second most common and deadliest type of cancer worldwide. Clinically, non-small cell lung cancer (NSCLC) is the most common pathologic form of lung cancer; approximately one-third…
View Post 8 min This content is machine translated Lung cancer An overview of non-small cell lung cancer across all stages The European Lung Cancer Congress is a joint project of major multidisciplinary societies representing thoracic oncology specialists working together to advance science, disseminate education and improve the practice of lung…
View Post 6 min This content is machine translated Non-small cell lung cancer Risk-adapted screening and treatment management Non-small cell lung carcinomas are the most common malignant tumors of the lung. 70–80% of all lung tumors can be assigned to this histology. A distinction can now be made…
View Post 15 min This content is machine translated Non-small cell lung cancer (NSCLC) Treatment strategies in metastatic ALK-positive and ROS1-positive NSCLC. The therapy of ALK-positive or ROS1-positive NSCLC has evolved greatly in recent years with the availability of various ALK or ROS1 inhibitors. This CME will summarize and discuss the current…
View Post 11 min This content is machine translated ASCO 2018 in Chicago Study news on lung, kidney and intestine KEYNOTE-042 and CARMENA: Two studies that have the potential to change practice. It’s about lung cancer – as so often lately – but also about renal cell carcinoma. Furthermore, the…
View Post 3 min This content is machine translated Personalized therapy for lung tumors Has platinum-containing first-line therapy had its day? Personalized immunotherapy is on track to replace chemotherapy in first-line non-small cell lung cancer. However, this only works for every second patient. Chemo vs. immuno-oncology – who will win the…
